nach oben

Erschienen in:

01.12.2012 | leitlinien für die praxis

Insulintherapie bei Diabetes mellitus

verfasst von: Monika Lechleitner, Michael Roden, Raimund Weitgasser, Bernhard Ludvik, Peter Fasching, Friedrich Hoppichler, Alexandra Kautzky-Willer, Guntram Schernthaner, Rudolf Prager, T. C. Wascher

Erschienen in: Wiener klinische Wochenschrift | Sonderheft 2/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende Leitlinien nimmt Bezug auf die praktische Umsetzung der Insulintherapie bei Typ 1 und Typ 2 Diabetes. Die unterschiedlichen Formen der Insulintherapie, sowie die Berechnung und Anpassung des Insulinbedarfs werden dargestellt.

Vorheriger Artikel Antihyperglykämische Therapie bei Diabetes mellitus Typ 2

Nächster Artikel Antihypertensive Therapie bei Diabetes mellitus

American Diabetes Association. Standards of medical care in diabetes-2012. Diabetes Care 2012, (Suppl 1:11–63).

Cheng A, Hanna A, Kader T, Richardson S. Insulin therapy in type 1 diabetes. Canadian Diabetes Association Clinical Practice Guidelines Expert Committee. 2008;46-52.

The Diabetes Control and Complication Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complication in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977–86.CrossRef

Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications Research Group. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563–69.CrossRef

Danemann D. Type 1 diabetes. Lancet 2006;367:847–58.CrossRef

De Boer IH, Rue TC, Cleary PA, Lachin JM, Molitch ME, et al. Long-term renal outcomes of patients with type 1 diabetes mellitus and microalbuminuria. Arch Intern Med 2011;171:412–20.PubMedCrossRef

Pop-Busui R, Herman WH, Feldman EL, Low PA, Martin CL, Cleary PA, Waberski BH, Lachin JM, Albrers JW: DCCT/EDIC Research Group. DCCT and EDIC studies in type 1 diabetes: lessons for diabetic neuropathy regarding metabolic memory and natural history. Curr Diab Rep 2010;10:276–82.PubMedCrossRef

White NH, Sun W, Cleary PA, Tamborlane WV, Danis RP, Hainsworth DP, Davis MD: DCCT-EDIC Research Group. Effect of prior intensive therapy in type 1 diabetes on 10-year progression of retinopathy in the DCCT/EDIC: comparison of adults and adolescents. Diabetes 2010;59:1244–53.PubMedCrossRef

Nathan DM, Cleary PA, Backlund Yu, et al. Diabetes Control and Complication Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med 2005;353:2643–53.PubMedCrossRef

10.

Gruden G, Giunti S, Barutta F, Chaturvedi N, Witte DR, Tricarico M, Fuller JH, Perin P, Bruno G. QTc interval prolongation is independently associated with severe hypoglycaemia attacks in type 1 diabetes from the EURODIAB IDDM complications study. Diabetes Care 2012;35:125–7.PubMedCrossRef

11.

UK Prospective Diabetes Study (UKPDS Group). Intensive blood glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837–52.CrossRef

12.

Holman RR, Paul SK, Bethel A, Matthews DR, Neil AW. 10-year follow up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577–89.PubMedCrossRef

13.

Duckworth W, Abraira C, Moritz, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med 2009;360:129–39.PubMedCrossRef

14.

ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560–72.CrossRef

15.

The Action to Control Cardiovascular Risk in Diabetes Study Group. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008;358:2545–59.CrossRef

16.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycaemia in type 2 diabetes: a patient-centered approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012;35:1364–79.PubMedCrossRef

17.

Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck, Peters AL, Tsapas A, Wender R, Matthews DR. Management of hyperglycämia in type 2 diabetes: a patient-centerd approach. Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2012.

18.

Ismail-Beigi F, Moghissi E, Tikin M, Hirsch IB, Inzucchi SE, Genuth S. Individualizing glycemic targets in type 2 diabetes mellitus: implications of recent clinical trials. Ann Intern Med 2011;154:554–9.PubMed

19.

Klonoff DC, Buckingham B, Christiiansen JS, Montori VM, Tamborlane WV, Vigersky RA, Wolpert H. Continuous glucose monitoring: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:2968–79.PubMedCrossRef

20.

Plank J, Siebenhofer A, Berghold A, et al. Systematic review and meta-analysis of short-acting insulin analogues in patients with diabetes mellitus. Arch Intern Med 2005;165:1337–44.PubMedCrossRef

21.

Horvath K, Jeitler K, Berghold A, Ebrahim SH, Gratzer TW, Plank J, Kaiser T, Pieber TR, Siebenhofer A. Long-acting insulin analogies versus NPH-insulin (human isophane insulin) for type 2 diabetes mellitus. Cochrane Database Syst Rev 2007;18:CD005613.

22.

Jensen MG, Hansen M, Brock B, Rungby J. Differences between long-acting insulins fort the treatment of type 2 diabetes. Exp Opin Pharmacother 2010;11:2027–35.CrossRef

23.

The ORIGIN Trial Investigators. Basal insulin and cardiovascular and other outcomes in dysglycemia. N Engl J Med 2012.

24.

Smith U, Gale EM. Does diabetes therapy influence the risk of cancer? Diabetologia 2009.

25.

Ruiter R, Visser LE, van Herk-Sukel MP, Coebergh JW, et al. Risk of cancer in patients on insulin glargin and other insulin analogues in comparison with those on human insulin: results from a large population-based follow-up study. Diabetologia 2012;55:51–62PubMedCrossRef

26.

Holman RR, Farmer AJ, Davies MJ, et al. 4-T Study Group. Three-year efficacy of complex insulin regimens in type 2 diabetes. N Engl J Med 2009;361:1736–1747PubMedCrossRef

27.

Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol 2012;18.

28.

Goudswaard AN, Furlong NJ, Valk GD, Stolk RP, Ruiten GEHM. Insulin monotherapy versus combination of insulin with oral hypoglycemic agents in patients with type 2 diabetes. Cochrane Database 2004:CD003418.

29.

Herman WH, Buse JB, Arakaki RF, Dungan KM, Jiang HH, Jacobson JG, Fahrbach JL. Concomitant oral antihyperglycemic agent use and associated outcomes after initiation of insulin therapy. Endocr Pract 2011;17:563–7.PubMedCrossRef

30.

Donner T, Munoz M. Update on insulin therapy for type 2 diabetes. J Clin Endocrinol 2012;97.

31.

Hemmingsen B, Christensen LL, Wetterslev J, Vaag A, Gluud C, Lund SS, Almdal T. Comparison of metformin and insulin versus insulin alone for type 2 diabetes: systematic review of randomised clinical trials with meta-analyses and trial sequential analyses. BMJ 2012;344:e1771CrossRef

Titel: Insulintherapie bei Diabetes mellitus
verfasst von: Monika Lechleitner
Michael Roden
Raimund Weitgasser
Bernhard Ludvik
Peter Fasching
Friedrich Hoppichler
Alexandra Kautzky-Willer
Guntram Schernthaner
Rudolf Prager
T. C. Wascher
Publikationsdatum: 01.12.2012
Verlag: Springer Vienna
Erschienen in: Wiener klinische Wochenschrift / Ausgabe Sonderheft 2/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI: https://doi.org/10.1007/s00508-012-0266-2

Springer Medizin Österreich

Zusammenfassung

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2012

Lipide: Diagnostik und Therapie bei Diabetes mellitus Typ 2

Lebensstil: Diagnostik und Therapie

Positionspapier: Exokrine Pankreasinsuffizienz und Diabetes mellitus

Positionspapier: Operation und Diabetes mellitus

Gravidität bei vorbestehendem Diabetes für die Leitlinien für die Praxis (AG Diabetes und Schwangerschaft der ÖDG)

Geschlechtsspezifische Aspekte für die klinische Praxis bei Prädiabetes und Diabetes mellitus